A challenging case of psoriasis flare-up after COVID-19 infection

Nasiri, Soheila; Araghi, Farnaz; Tabary, Mohammadreza; Gheisari, Mehdi; Mahboubi-Fooladi, Zahra; Dadkhahfar, Sahar

doi:10.1080/09546634.2020.1764904

Cited by 30 publications

(37 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hereby, it can be differentiated between drugs that in general show immunomodulatory properties or drugs that target a specific cytokine that is related to CRS. Therapeutics that show immunomodulatory properties currently evaluated comprise Thalidomide [ 210 ], Methylprednisolone [ 209 ], Fingolimod [ 211 ], Ruxolitinib [ 212 ], Eculizumab [ 213 ], Leukine [ 214 ], Colchicine [ 215 ], Vafidemstat [ 216 ], Melatonin [ 217 ], Nivolumab [ 218 ], Dexamethasone [ 219 ] or Cyclosporine A [ 220 , 221 ].…”

Section: Therapeutic Interventions and Nanomedicine Strategiesmentioning

confidence: 99%

Nanomedicine strategies to target coronavirus

2020

View full text Add to dashboard Cite

show abstract

Section: Therapeutic Interventions and Nanomedicine Strategiesmentioning

confidence: 99%

Nanomedicine strategies to target coronavirus

2020

View full text Add to dashboard Cite

show abstract

“…Individual patient data were pooled from 10 reports. [10][11][12][13][14][15][16][17][18][19] Categorical variables are described as absolute frequencies and percentages and continuous variables are presented as mean values ± SD (SD). Fisher and t-test were used to compare variables between subjects with or without hospitalization.…”

Section: Discussionmentioning

confidence: 99%

“…We excluded four patients from three reports 14,15,17 for the comorbidity descriptive and pooled analysis because of unclear/ missing data.…”

Section: Missing Datamentioning

confidence: 99%

Effect of immunosuppressive drugs in immune‐mediated inflammatory disease during the coronavirus pandemic

Giuliani

Gualdi

Amerio

2020

Dermatologic Therapy

View full text Add to dashboard Cite

The safety of immunosuppressive treatment in patients with Immune‐Mediated Inflammatory Diseases (IMIDs) during the Coronavirus pandemic is questioned and it is utmost important for public health. We searched studies trough MEDLINE/EMBASE database, including patient with IMID, undergoing immunosuppressive treatment with a positive diagnosis for SARS‐CoV 2. We included 11 studies for the descriptive analysis and 10 studies for the pooled analysis, with a total population of 57 and 53 IMID‐affected SARS‐CoV‐positive patients respectively. Overall no death was reported; 16 patients were hospitalized (30.2%) and only 2 cases were admitted to Intensive Care Unit (ICU) (3.8%). We found a significant association between the risk of hospitalization and older age (p 0.03), obesity (p 0.02) and presence of multi‐comorbidity (p 0.03) . No significant association was found between the risk of hospitalization and the use of biological or conventional DMARDs (respectively p 0.32 and 0.26), neither when they are used combined (p 0.85) . We found consistent results in the sub‐analysis of Psoriasis: 10 patients were hospitalized (31.3%) and only 1 case was admitted to Intensive Care Unit (ICU) (3.1%) Particular attention should be placed for patients with older age, obesity and multi‐comorbidity that are at higher risk of hospitalization. This article is protected by copyright. All rights reserved.

show abstract

“…Studies in March, early April were comments based on expert opinions, 6 and studies of case‐series in May provided additional evidence to guide the usage of these drugs 7 . The dermatologists are recommended to read these publications to weigh and judge the risks and benefits, for discontinued usage of biologics may decrease the infection risk of COVID‐19 and lead to the aggravation of primary diseases at the same time 8,9 …”

Section: Discussionmentioning

confidence: 99%

Contributions of dermatologists to COVID ‐19 research: A brief systematic review

Wang

Fang

Zhang

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID‐19) has been declared a pandemic. We conducted a systematic review to reveal the contribution of dermatologists in COVID‐19 research. Two hundred and ninety‐eight articles were included and classified into cutaneous manifestations of COVID‐19, operating experience against COVID‐19, mechanisms and treatment of COVID‐19, disinfection and personal protective equipment (PPE)‐related skin diseases, and other topics. The value of these articles and their impact on clinical impact were discussed and we hope that dermatologists can have a better understanding of these areas from this study.

show abstract

A challenging case of psoriasis flare-up after COVID-19 infection

Cited by 30 publications

References 2 publications

Nanomedicine strategies to target coronavirus

Nanomedicine strategies to target coronavirus

Effect of immunosuppressive drugs in immune‐mediated inflammatory disease during the coronavirus pandemic

Contributions of dermatologists to COVID ‐19 research: A brief systematic review

Contact Info

Product

Resources

About